Biodexa Pharmaceuticals (BDRX) Net Income (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Net Income of -$5.3 million for Q2 2025, down 16.0% sequentially from -$4.6 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Net Income (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Net Income for 13 years, with the latest figure at -$5.3 million in Q2 2025.
- Quarterly Net Income changed N/A year-over-year to -$5.3 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$9.9 million (up 47.2% YoY) and the FY2025 annual result came in at -$8.4 million, down 14.47% from the prior year.
- Net Income fell to -$5.3 million in Q2 2025 per BDRX's latest filing, from -$4.6 million in the prior quarter.
- Over five years, Net Income peaked at -$4.4 million in Q3 2021 and troughed at -$10.4 million in Q4 2022.
- A 5-year average of -$6.5 million and a median of -$5.1 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2021 and 2022: Net Income jumped 80.02% in 2021, then fell 21.83% in 2022.
- Over 5 years, Net Income stood at -$8.5 million in 2021, then retreated by 21.83% to -$10.4 million in 2022, then climbed by 10.81% to -$9.3 million in 2023, then soared by 50.84% to -$4.6 million in 2024, then slipped by 16.0% to -$5.3 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$5.3 million, -$4.6 million, and -$9.3 million for Q2 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.30 Mn |
| Dec 31, 2024 | -4.57 Mn |
| Dec 31, 2023 | -9.29 Mn |
| Jun 30, 2023 | -4.83 Mn |
| Dec 31, 2022 | -10.42 Mn |
| Sep 14, 2022 | -4.62 Mn |
| Dec 31, 2021 | -8.55 Mn |
| Sep 17, 2021 | -4.38 Mn |
| Dec 31, 2020 | -23.00 Mn |
| Sep 10, 2020 | -21.94 Mn |
| Dec 31, 2019 | -5.68 Mn |
| Dec 31, 2018 | -6.00 Mn |
| Dec 31, 2017 | -5.79 Mn |
| Dec 31, 2016 | -25.07 Mn |
| Dec 31, 2015 | -15.33 Mn |
| Dec 31, 2014 | -13.98 Mn |
| Dec 31, 2013 | -6.61 Mn |